搜索到 1000 条关于 까치산스타킹룸ヵotam13、coм 까치산풀싸롱 까치산키스방 까치산패티쉬룸 까치산미러룸 的文章

2012.09.19 美国医疗展|2011年美国迈阿密国际医疗器械展(FIME 2011)

Exit & Entry Co.,Ltd邱先生 Mr. andy-ku电话

2012.09.19 第十一届中国国际多肽学术会议 2010CPS

PharmaceuticalCo., Ltd, / China]Songping Liang [Hunan normal University/ China

2018.10.29 上海 12 月 13-15 日举办「第二期药物研发质量管理运行难点实施及临床试验用药物 GMP 实施关键点控制」高级研修班的通知(李永康专场)

质量管理广泛关注的问题和面临的困惑。为此我单位定于 2018 年 12 月 13-15 日在上海市举办「第二期药物研发质量管理运行中的难点实施及临床试验用药物 GMP 实施关键点控制」高级研修班。现将有关培训事项通知如下:一、会议安排会议时间:2018 年 12 月 13---15 日 (13 日全天报到) 报到地点:上海市

2012.09.19 第二届亚洲阿登制药技术研讨会暨中国药学会药剂专业委员会2010年学术年会

由我会和美国药学科学家协会(American Association of Pharmaceutical Scientists)、中国药学会药剂专业委员会共同主办、沈阳药科大学和辽宁省药学会承办的“第二届亚洲阿登制药技术研讨会暨中国药学会药剂专业委员会2010年学术年会”将于2010年6月在沈阳召开,会议主题为“难溶药物的剂型策略”。药物溶解行为一直是生物药学分类系统II级和IV级原料药剂型研发中最具挑战性的难题之一,近年来随着组合化学和高通量筛选技术的出现,难溶性备选药物的数目显著增多。在此背景下,旨在交流国内难溶药物制剂研究的进展,了解和学习国际同行在难溶药物剂型方面的最新技术和发展趋势,召开本次阿登会议。会议分为两部分,第一部分为中国药学会药剂专业委员会2010年学术年会,会期一天,报告人由优秀论文作者和国内知名药剂专家组成,会议重点研讨国内在难溶药物制剂研究方面的进展;第二部分为阿登会议,届时将邀请难溶药物制剂研究方面的国际知名专家做精彩报告,并鼓励与会代表与报告人进行深入讨论和案例研究。会议首日将着重介绍药物溶解度,解析生物药学分类系统、药物溶解度的调节及其预测,并深入阐述液体剂型相关内容。第二日将侧重探讨固体剂型,从生产和法规角度阐述增溶技术,如超临界流体工艺、喷雾干燥、熔融挤压、冷冻干燥和QbD(质量源于设计,Quality by Design)等议题。具体会议信息如下:一、会议时间:2010年6月11日-13日,会期3天。6月10日 报到;
6月11日 召开中国药学会制剂专业委员会2010年学术年会;
6月12-13日 召开阿登会议。二、会议地点:沈阳·凯宾斯基饭店,沈阳市沈河区青年大街109号,024-22988988三、会议学分:授予参会代表中国药学会继续药学教育I类学分8分。四、会议语言:中英文,阿登会部分拟设中英同声传译。五、大会顾问委员会(Advisory Committee):主席:吴春福 教授,沈阳药科大学 校长Dr. Ping Lee,University of Toronto, Canada委员:Dr. Gordon Amidon, University of Michigan, USA
侯惠民,上海医药工业研究院,中国工程院
Dr. Tsuneji Nagai, The Nagai Foundation Tokyo, Japan
Dr. Kinam Park, Purdue University, USA六、大会议程委员会(Planning Committee)主席:张强 教授,北京大学医学部药学院Jian-Xin Li, Ph.D., Evonik-Degussa Corporation, USA副主席:
潘卫三 教授,沈阳药科大学
Geoff G.Z. Zhang, Ph.D. Abbott Laboratories, US
蒋新国 教授,复旦大学药学院
张志荣 教授,四川大学药学院
周建平 教授,中国药科大学药学院委员:委员由中国药学会药剂专业委员会担任七、会议征文:(一)征文主题及格式:请围绕大会主题“难溶药物的剂型策略”,包括液体制剂、固体制剂、纳米粒及颗粒工程学、提高难溶药物溶解度和吸收的相关技术等相关内容积极投稿。所提交的论文要求同时提交中英文摘要。所有入选论文将被收录到会议论文集,优秀论文作者将被邀请做大会交流。稿件要求控制在2000字以内,统一采用Word文档编辑,论文格式及参考文献格式请参照《中国药学杂志》稿约要求(具体请访问中国药学杂志约稿须知网站 http://www.zgyxzz.com.cn/tx/Index.asp)。请将电子版通过E-mail提交,工作人员将在收到稿件后一周内回信确认。(二)征文截止日期:2010年5月20日。(三)提交方式:可直接发送论文至yxgpaper@163.com,或致电024-23986315联系沈阳药科大学,潘卫三 杨星钢八、大会注册及住宿安排(一)注册费标准:1.5月15日前:2200 RMB/人,含会议资料,招待酒会,会议期间自助午、晚餐,会议期间茶歇等,住宿费自理。
2.5月15日后:2800 RMB/人。
3.中国药学会在册的高级会员,注册费按照上述标准优惠200 RMB /人。电汇或邮局汇款时,请在备注栏注明高级会员证号,现场注册请携带高级会员证。
4. 全日制在校研究生按照 1200 RMB/人标准收费,凭学生证报到。
5. 代表报到时间:6月10日上午8点至下午6点。
6. 注册费汇款账号信息请见报名表。(二)住宿会议酒店:沈阳?凯宾斯基饭店,沈阳市沈河区青年大街109号,024-22988988。
住宿收费标准:单人房500元/天(含1份早餐),双人房为260元/床(含1份早餐)。请在报名表上标明住房需要。(三)会议注册联系方式1. 沈阳药科大学
联系人:赵临襄 陈大华
电 话:024-23986083
传 真:024-23896576
E-mail:sypukyc@163.net2. 辽宁省药学会
联系人:刘 彤
电 话:024-25431229 13386860238
传 真:024-25431229
E-mail:newlnyxh@sina.com3. 中国药学会
联系人:张子烨 刘春光
电 话:010-58699271 010-58699280转822
传 真:010-58699272
E-mail: arden@cpa.org.cn
地 址:北京市朝阳区建外大街四号建外SOHO九号楼18层1802室
邮 编:100022九、大会初步议程2010年6月10日,星期四
8:30 am - 6:15 pm 大会报到2010年6月12日,星期五
8:30 am - 5:30 pm 中国药学会药剂专业委员会2010年学术年会2010年6月12日,星期六Session I. Drug Solubility 第一节 药物溶解度
8:30 am - 9:15 am
Key Note Address: Insoluble Compounds: Current Trend in Drug Discovery Pipeline and Formulation Challenges重点演讲:不溶化合物:药物研发方法和剂型创新的当前趋势
Anil M. Salpekar, Ph.D.,Solvay Pharmaceuticals, Inc., 荷兰
9:15 am – 10:00 am
Why Compounds Are Insoluble and What We Can Do About It? 为什么化合物不溶,我们能做什么?
Valentino J. Stella Ph.D.University of Kansas, 美国
10:00 am – 10:15 am 茶休
10:15 am – 11:00 pm
In Vitro Dissolution Test Methods for Formulation Development of Poorly Soluble Drugs: Challenges and Opportunities 难溶药剂型开发的体外溶解测试方法:挑战与机遇
Yi Shi, Ph.D.Abbott Laboratories,美国
11:00 am – 11:45 am
Solubilization Techniques 增溶技术
Valentino J. Stella Ph.D.University of Kansas,美国
11:45 am – 1:00 pm 午餐
1:00 pm – 1:45 pm
BCS and Implications for Drug Formulations 生物药学分类系统及其在药物剂型方面的应用
Sherry Ku, Ph.D.Pfizer,美国
1:45 pm – 2:00 pm
Inhibiting Crystallization in Solution: Characterization and Application
抑制溶液结晶:表征及应用
Ping Gao, Ph.D.Abbott Laboratories,美国
2:00 pm-2:15 pm
Break茶休Session II: Liquid Formulations 第二节:液体制剂
2:15 pm-3:00 pm
Nanosuspensions for the Delivery of Poorly Soluble Drugs
纳米悬浮液用于难溶药物给药系统
Rainer H. Müller, Ph.D. Free University of Berlin,德国
3:00 pm -3:45 pm
Lipid Based Formulation Approaches
基于脂类的制剂方法
Ron Liu,Austar Pharma, LLC,美国
3:45 pm -4:30 pm
Self-Emulsifying Formulations for Oral Delivery of Poorly Soluble Drugs
自乳化剂用于口服难溶药物制剂
Ping Gao, Ph.D.Abbott Laboratories,美国
4:30 pm -5:00 pm
Panel Discussion 小组讨论2010年6月13日,星期日Session III Solid Formulations 第三节 固体制剂
8:30 am - 9:15 am
Amorphous Solid Dispersions and Solid Solutions: Dissolution Enhancement and Physical Stability
非晶态固体分散体和固体溶液:增加溶解和物理稳定性
Lian Yu, Ph.D.Wisconsin University,美国
9:15 am - 10:00 am
Crystalline Solid Dispersions 结晶固态分散体
Geoff G.Z. Zhang, Ph.D.Abbott Laboratories,美国
10:00 am – 10:15 am 茶休
10:15 am - 11:00 am
Spray Drying 喷雾干燥
Randy Wald, Ph.D.Bend Research Inc.,美国
11:00 pm – 11:45 am
Solubility Enhancement by Hot Melt Extrusion
熔融挤压法提高溶解度
Jian-Xin Li, Ph.D.Evonik-Degussa Corporation,美国
11:45 am – 1:00 pm 午餐
1:00 pm – 1:45 pm
Case Study: First-in-Human Formulations for Poorly Soluble APIs
案例研究:难溶原料药的首次人用剂型
Sherry Ku, Ph.D.Pfizer,美国
1:45 pm – 2:30 pm
Regulatory Issues on Particle Size Specifications
颗粒尺寸规格的法规议题
Zhigang Sun, Ph.D. U.S. Food and Drug Administration,美国
2:30 pm – 2:45 pm 茶休
2:45 pm – 3:30 pm
Scalable Manufacturing of Poorly Soluble Products
难溶产品的可扩展生产
Michael Lowinger, Ph.D. Merck & Co., Inc.,美国
3:30 pm – 4:15 pm
Regulatory Issues/QbD for Poorly Soluble Products
基于难溶产品的法规议题/质量源于设计
Lawrence Yu, Ph.D. U.S. Food and Drug Administration,美国
4:15 pm – 5:00 pm
Final Discussion and Closing Remarks,Speakers and Chairperson
最终讨论和闭幕式,讲者及主席说明:最终准确议程请以最后会议手册为准
第七届中国生物制药峰会

2020.01.19 第七届中国生物制药峰会

-13:00OPENING REMARKS 开幕及主持CCCMHPIE中国医药保健品进出口商会13:00-13:30全球生物药市场概况及行业交易纵览... Divisio王刚 博士,科睿唯安,生命科学与制药事业部 首席科学家13:30-14:00从 biotech 到 biopharma,以 PD-1
2013年度生物公司研发投入20强

2014.07.16 2013年度生物公司研发投入20强

%4BD (Becton, Dickinson & Co.)494472...133132.60.30%13

2006.01.11 高龄已不是中风病人溶栓的禁忌症

of outcome, Swiss researchers report in the December 13th issue of Neurology.Dr...., co-author of an accompanying editorial told Reuters Health, "IV rt-PA should

2012.09.19 【免注册费】上海分子流行病学与GWAS会议国际研讨会

分子流行病学再揭示人类复杂疾病遗传因素及其与环境因素相互作用发挥重要作用,为人类疾病的风险评估、预防和个性化治疗提供依据。全基因组关联分析(GWAS)为全面系统研究复杂疾病的遗传因素掀开了新的一页,为我们了解人类复杂疾病的发病机制提供了更多的线索。科学家已经在肥胖、糖尿病、冠心病、阿尔茨海默、乳腺癌、前列腺癌、肺癌、胃癌等一系列复杂疾病中进行了全基因组关联研究并找到疾病相关的易感基因,我国科学家也在银屑病、精神病和冠心病等方面开展了GWAS研究并取得成效。国家科技部最新公布了“常见重大疾病全基因组关联分析和药物基因组学研究”的863重点项目,吹响了我国大规模开展GWAS研究的号角。为了让更多的相关研究人员,特别是广大研究生了解GWAS的研究原理和方法,学会设计GWAS的研究和分析实验结果,同时在癌症领域分享海内外研究专家们的成功经验,并期待在GWAS方面进行交流合作,复旦大学和美国Van Andel 研究所将于2009年7月12-14日在上海联合举办上海分子流行病学与GWAS国际 研讨会, 期待各位同道免费参加,请有意者及时将回执返回联系邮箱。免注册费(食宿餐饮费用自理)。名额有限,报名从速!时间: 2009年7月12-14日
报到地点: 复旦大学卿云楼宾馆 上海市邯郸路220号,200433
会议地点: 复旦大学逸夫楼报告厅
联 系 人: 赵雪莹 高歌 联系电话: 021-55664495
回执邮箱: GWAS2009@gmail.com
BackgroundRecent success of genome-wide association studies (GWAS) in the U.S. and Europe has lead to the identification of a large number of genetic variants that are associated with disease risk and progression, including those for cancer and cardiovascular diseases. The discovery of these genetic markers not only improves our understanding of disease etiology, but also contributes significantly to risk prediction, early detection, and targeted treatment of diseases.Although GWAS have been used in Chinese populations to identify Chinese-specific risk-associated genetic variants for several common diseases such as breast cancer and psoriasis, many more GWAS are needed for various diseases. A better understanding of the importance of GWAS and a better knowledge of study design and data analysis of GWAS will further promote broad application of GWAS in China. This symposium which will cover genetic epidemiology and GWAS in China is organized to serve this purpose. We have invited a group of experts in this area from the U.S. and China to share their experience in GWAS, and we hope to foster an environment which will encourage an open discussion among all participants.
Objectives• To better understand the potential applications of GWAS
• To address practical issues in study design, implementation, and data analysis of GWAS
• To promote interaction and collaboration among researchers who are interested in GWAS
• To explore other important studies after GWAS: gene-environment interaction, risk prediction, and functional analyses
• To consider issues and implications related to genomic and personalize medicine
Organizing committeeThe organizing committee consists of four members:
Dr. Jianfeng Xu (Co-Chair)
Dr. Daru Lu (Co-Chair)
Dr. Li Jin (Co-Chair ,Advisor)
Dr. Qingyi Wei (Co-Chair, Advisor)
PresentationsSession I: Genetic epidemiology and GWAS of cancer
• Breast cancer in Chinese populations Xiao-ou Shu
• Genetic association studies of skin cancer Jiali Han
• Genetic variants in the MC1R gene and risk of cutaneous melanoma Qingyi Wei
• Genetic association studies of lung cancer in Chinese populations Daru Lu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao Zhou
• Molecular epidemiology of stomach cancer Weimin YeSession II: Genetic epidemiology and GWAS of other diseases
• Genetic association studies of hypertension in Chinese populations Jiang He
• GWAS of Autoimmune Diseases (Psoriasis, etc.) in Chinese populations Wei Huang
• Molecular epidemiology of diabetes in Chinese populations Weiping Jia
• Molecular genetics study of hypertension in Chinese populations Dingliang Zhu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao ZhouSession III: Post-GWAS studies
• Genetic structure of Chinese population Li Jin
• High-throughput genotyping for GWAS and fine mapping studies Siqun Lilly Zheng
• Molecular genetics study of neural tube defect Hongyan Wang
• Risk prediction using genetic variants in prostate cancer Jianfeng Xu
• Gene-environmental interaction in smoking related cancer Zuo-Feng Zhang
• Cancer Somatic Genomics Bin TehSession IV: Short presentations by participants and discussion
Registration时  间: 2009年7月12-14日
报到地点: 复旦大学卿云楼宾馆大厅 上海市邯郸路220号 (200433)
会议地点: 复旦大学逸夫楼报告厅
联 系 人: 赵雪莹,高歌 (Shanghai, China);Tamara Adams (U.S.)
联系电话: 21-55664495 (Shanghai, China);336-713-7532 (U.S.)
回执邮箱: GWAS2009@gmail.com (Shanghai, China);tsadams@wfubmc.edu (U.S.)
Invited speakers (alphabetic)• Jiali Han, Ph.D., is an Assistant Professor of Medicine at Harvard Medical School. His major research areas are:
• Genetic epidemiology of skin cancer and breast cancer
• Genome-wide association studies
• Gene-environment interaction• Jiang He, M.D. Ph.D., is a Professor and Chair of Epidemiology, Tulane University School of Public Health., U.S.A. His major research areas are:
• Genetic epidemiology of hypertension
• Gene-nutrition interaction of cardiovascular disease• Wei Huang, Ph.D., is a Professor and Executive Deputy Director of Chinese National Human Genome Center at Shanghai, China. Her major research areas are:
• Genetic susceptibility to autoimmune diseases, cardiovascular diseases and cancer.
• Genome-wide association studies
• Genetic variants and association study• Weiping Jia M.D., is a professor of endocrinology at Shanghai Institute of Diabetes, Shanghai No.6 People’s Hospital, Shanghai Jiaotong University, Her major research area is:
• Molecular endocrinology and diabetes• Li Jin, Ph.D, is a Professor of Genetics and vice President of Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolism diseases
• Genetic markers for population genetics• Daru Lu, Ph.D, is a Professor of Genetics and Vice Dean of School of Life Sciences, Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolic disease• Xiao-ou Shu, M.D, Ph,D, is a Professor of Medicine in the Department of Medicine at the Vanderbilt University School of Medicine, U.S.A. Her major research areas are:
• Genetic and lifestyle predictors of cancer and other chronic diseases
Cohort study methodology
• Incorporating biomarkers in risk prediction• Bin Teh, M.D, is a Distinguished Scientific Investigator at Van Andel Institute, U.S.A. His major research areas are:
• Translational cancer research
• Gene expression profiling
• Cancer genome high-throughput sequencing• Hongyan Wang, Ph.D, is a professor of genetics at School of Life sciences, Fudan University, China. Her major research area is:
• Molecular genetics and epidemiology of birth defects (deformity of neural tube, congenital heart disease, etc.)• Qingyi Wei, M.D, Ph.D, is a Professor of Epidemiology at The University of Texas M. D. Anderson Cancer Center, U.S.A. His major research areas are:
• Molecular epidemiology of DNA repair, apoptosis, and skin cancer and head and neck cancer
• Genetic susceptibility to cancer
• DNA repair and apoptosis phenotype markers• Jianfeng Xu, M.D, Dr.PH, is a Professor of Epidemiology and Cancer Biology and Director of the Center for Cancer Genomics at Wake Forest University School of Medicine, U.S.A. His major research areas are:
• Genetic epidemiology of prostate cancer
• Genome-wide association and fine mapping analysis
• Risk prediction using genetic markers and other clinicopathologic variables• Zuo-Feng Zhang, M.D., Ph.D, is a Professor of Epidemiology at UCLA School of Public Health, U.S.A. His major research areas are:
• Molecular epidemiology of smoking-related cancers
Confirmation studies of SNPs identified in genome-wide association studies in smoking-related cancers
• Gene-environmental interaction between genetic markers and environmental factors• S. Lilly Zheng, M.D, is a Professor of Medicine and Director of the Genotyping Laboratory at Wake Forest University School of Medicine. U.S.A. Her major research areas are:
• High-throughput genotyping and sequencing
• Genetic epidemiology of prostate cancer• Gangqiao Zhou, Ph.D, is a Professor of Medical Genetics and Genomics in National Academy of Military Medical Science. His major research area is:
• molecular and genetics of complex diseases• Dingliang Zhu, M.D, is a professor of cardiology at Shanghai Institute of Hypertension, Shanghai, China. His major research area is:
• Molecular and genetics of cardiovascular diseases• Weimin Ye, Ph.D, is a Professor of Medical Epidemiology at Karolinska Institutet, Sweden. His major research areas are: Etiology of upper gastrointestinal diseases
• Topic of presentation: Molecular epidemiology of stomach cancer
检验案例:警惕ELISA检测梅毒抗体中的假阴性

2016.11.13 检验案例:警惕ELISA检测梅毒抗体中的假阴性

S/CO≥1,初步判定为阳性,挑出后用 TPPA 进行确认,同时做 TRUST 检测滴度。如果 TPPA 为阳性,报梅毒抗体阳性和 TRUST 滴度,如果 TPPA 为阴性,报梅毒抗体阴性。而 S/CO<1,直接就按阴性标本发送结果。虽然,WB 才是梅毒螺旋体抗体的确认实验,但在临床工作中这项工作很难开展,而 TPPA
2016 年世界胸科大会——氢分子医学与肺部疾病学术论坛

2016.04.06 2016 年世界胸科大会——氢分子医学与肺部疾病学术论坛

;Organizer:China International Medical Foundation协办:上海潓美医疗科技有限公司Co-organizer:hanghai Asclepius Meditec Co.,Ltd电话:021-23123512email

2011.12.12 盐酸沙格雷酯能够防止高糖诱导的血管内皮功能障碍和氧化性应激

and presence of sarpogrelate hydrochloride. Co-incubation of aortic rings... no effects on EIR. After incubation of the rings in the co-presence of sarpogrelate
超详细版血气分析攻略  值得你一看

2017.06.24 超详细版血气分析攻略 值得你一看

酸碱平衡失调;② 不能区别(PH 异常时)是呼吸性或失代偿性酸/碱平衡失调。例 1. PH 正常有三种情况:①HCO3-和 H2CO3 数值均正常范围.②HCO3-↓/H2CO3↓③HCO3-↑/H2CO3↑虽然 PH 值正常,但单看 PH 值无法判断是否存在代偿性酸碱平衡失调。例 2. PH↑可能是 HCO3-
科技写作之如何设计写作提纲?

2014.05.06 科技写作之如何设计写作提纲?

CO2concentrations affect flowering plantsA. Background:1. General... decreased due to climate change (Joh et al., 1999)ii. CO2concentration has

2007.09.09 慢阻肺:无创通气治疗对慢性阻塞性肺病合并睡眠呼吸暂停患者呼吸中枢反应性的影响

综合征(SAHS)患者,其中5 例合并COPD,平均FEV1/FVC 为59±6%,5 例为伴CO2 潴留的SAHS 患者,FEV1/FVC 正常。二...(ΔVE/ΔSaO2)及高CO2 反应性(ΔVE/ΔPaCO2 )。结果表明:OS 及OSA 患者治疗前的呼吸中枢

2006.01.11 症状性和无症状性颈内动脉闭塞的患者对侧颈动脉内膜剥脱术对血流动力学的影响.10年的随访研究

with severe (>70%) carotid artery stenosis contralateral to carotid occlusion (CO). Thirty-nine patients with severe carotid lesion contralateral to CO were
【用药问答】容易引起Ⅱ型呼衰加重的药物是?

2022.01.24 【用药问答】容易引起Ⅱ型呼衰加重的药物是?

CO2潴留时,随 PaCO2升高可表现为先兴奋后抑制现象。兴奋症状包括失眠、烦躁、躁动、夜间失眠而白天嗜睡(昼夜颠倒现象)等,但此时切忌应用镇静或催眠药,以免加重 CO2潴留,诱发肺性脑病。(选 D)呼吸兴奋剂对于气道通畅、呼吸肌功能基本正的患者可以使用,通过增加肺通气加快
快速查明昏迷病因 只需记住 1 个单词

2016.01.11 快速查明昏迷病因 只需记住 1 个单词

分 诊断思路患者中年男性急性起病,昏迷。定位:脑实质的广泛受累,或上行网状激活系统受累。定性:急性昏迷可见于心脑血管疾病、各类中毒(CO 中毒、有机磷中毒、镇静药...无头痛、恶心及呕吐,脑炎排除。此时正值冬季,患者身处东北地区,遂追家属是否应用煤炉取暖,有无 CO 接触史。患者家属肯定了此种可能:家属诉家中应用煤炉取暖
上一页 1 2 3 ... 33 34 35 ... 48 49 50 下一页 到第